Osiris Therapeutics, Inc.  

(Public, NASDAQ:OSIR)   Watch this stock  
Find more results for OSIR
-0.41 (-3.20%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.33 - 13.03
52 week 10.00 - 27.40
Open 12.75
Vol / Avg. 272,435.00/276,410.00
Mkt cap 424.00M
P/E 408.64
Div/yield     -
EPS 0.03
Shares 34.22M
Beta 0.72
Inst. own 37%
May 6, 2014
OSIRIS THERAPEUTICS INC Annual Shareholder Meeting - 2:00PM EDT - Add to calendar
May 5, 2014
Q1 2014 OSIRIS THERAPEUTICS INC Earnings Release (Estimated) Add to calendar
Mar 26, 2014
OSIRIS THERAPEUTICS INC at Alliance for Regenerative Medicine RegenMed Investor Day
Mar 11, 2014
OSIRIS THERAPEUTICS INC at Canaccord Genuity's Musculoskeletal Conference
Mar 5, 2014
Q4 2013 OSIRIS THERAPEUTICS INC Earnings Release
Mar 5, 2014
Q4 2013 OSIRIS THERAPEUTICS INC Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 45.88% 4.66%
Operating margin -2.20% -11.65%
EBITD margin - -9.24%
Return on average assets 22.55% 1.70%
Return on average equity 26.39% 1.94%
Employees 59 -
CDP Score - -


7015 Albert Einstein Drive
United States - Map
+1-443-5451800 (Phone)
+1-443-5451701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Osiris Therapeutics, Inc. (Osiris), is a stem cell therapeutic company. The Company focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The Company operates in two business segments: Therapeutics and Biosurgery. The Company's Therapeutics business is focused on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Company's Biosurgery business, works to harness the ability of cells and novel constructs to promote the body's natural healing. In the Company's Biosurgery business, the Company manufactures , market and distributes Grafix and Ovation for tissue repair. In the Company's Therapeutics segment, its pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee.

Officers and directors

Peter Friedli Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Lode Debrabandere Ph.D. President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Philip R. Jacoby Jr. Chief Financial Officer, Treasurer, Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Michelle LeRoux Williams Ph.D. Chief Scientific Officer
Age: 38
Bio & Compensation  - Reuters
Felix Gutzwiller M.D., Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Hans Klingemann M.D., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Jay M. Moyes Independent Director
Age: 59
Bio & Compensation  - Reuters